|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Argiris A, Karamouzis M, Raben D and
Ferris R: Head and neck cancer. Lancet. 371:1695–1709. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cohen P and Frame S: The renaissance of
GSK3. Nat Rev Mol Cell Biol. 2:769–776. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Diehl JA, Cheng M, Roussel MF and Sherr
CJ: Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis
and subcellular localization. Genes Dev. 12:3499–3511. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rubinfeld B, Albert I, Porfir E, Fiol C,
Munemitsu S and Polakis P: Binding of GSK3beta to the
APC-beta-catenin complex and regulation of complex assembly.
Science. 272:1023–1026. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sears R, Nuckolls F, Haura E, Taya Y,
Tamai K and Nevins JR: Multiple Ras-dependent phosphorylation
pathways regulate Myc protein stability. Genes Dev. 14:2501–2514.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ougolkov AV, Fernandez-Zapico ME, Savoy
DN, Urrutia RA and Billadeau DD: Glycogen synthase kinase-3beta
participates in nuclear factor kappaB-mediated gene transcription
and cell survival in pancreatic cancer cells. Cancer Res.
65:2076–2081. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shakoori A, Ougolkov A, Yu ZW, Zhang B,
Modarressi M, Billadeau D, Mai M, Takahashi Y and Minamoto T:
Deregulated GSK3beta activity in colorectal cancer: Its association
with tumor cell survival and proliferation. Biochem Biophys Res
Commun. 334:1365–1373. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gaisina IN, Gallier F, Ougolkov AV, Kim
KH, Kurome T, Guo S, Holzle D, Luchini DN, Blond SY, Billadeau DD
and Kozikowski AP: From a natural product lead to the
identification of potent and selective
benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase
3beta inhibitors that suppress proliferation and survival of
pancreatic cancer cells. J Med Chem. 52:1853–1863. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ougolkov AV, Fernandez-Zapico ME, Bilim
VN, Smyrk TC, Chari ST and Billadeau DD: Aberrant nuclear
accumulation of glycogen synthase kinase-3beta in human pancreatic
cancer: Association with kinase activity and tumor
dedifferentiation. Clin Cancer Res. 12:5074–5081. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ougolkov AV, Bone ND, Fernandez-Zapico ME,
Kay NE and Billadeau DD: Inhibition of glycogen synthase kinase-3
activity leads to epigenetic silencing of nuclear factor kappaB
target genes and induction of apoptosis in chronic lymphocytic
leukemia B cells. Blood. 110:735–742. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bilim V, Ougolkov A, Yuuki K, Naito S,
Kawazoe H, Muto A, Oya M, Billadeau D, Motoyama T and Tomita Y:
Glycogen synthase kinase-3: A new therapeutic target in renal cell
carcinoma. Br J Cancer. 101:2005–2014. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Naito S, Bilim V, Yuuki K, Ugolkov A,
Motoyama T, Nagaoka A, Kato T and Tomita Y: Glycogen synthase
kinase-3beta: A prognostic marker and a potential therapeutic
target in human bladder cancer. Clin Cancer Res. 16:5124–5132.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cao Q, Lu X and Feng Y: Glycogen synthase
kinase-3beta positively regulates the proliferation of human
ovarian cancer cells. Cell Res. 16:671–677. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA
and Chen H: Inactivation of glycogen synthase kinase-3beta, a
downstream target of the raf-1 pathway, is associated with growth
suppression in medullary thyroid cancer cells. Mol Cancer Ther.
6:1151–1158. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Miyashita K, Kawakami K, Nakada M, Mai W,
Shakoori A, Fujisawa H, Hayashi Y, Hamada J and Minamoto T:
Potential therapeutic effect of glycogen synthase kinase 3beta
inhibition against human glioblastoma. Clin Cancer Res. 15:887–897.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu Q, Yang J, Han S, Liu J, Holzbeierlein
J, Thrashe JB and Li B: Suppression of glycogen synthase kinase 3
activity reduces tumor growth of prostate cancer in vivo. Prostate.
71:835–845. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang Z, Smith KS, Murphy M, Piloto O,
Somervaille TC and Cleary ML: Glycogen synthase kinase 3 in MLL
leukaemia maintenance and targeted therapy. Nature. 455:1205–1209.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin
O and Woodgett JR: Requirement for glycogen synthase kinase-3beta
in cell survival and NF-kappaB activation. Nature. 406:86–90. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Aggarwal BB: Nuclear factor-kappaB: The
enemy within. Cancer Cell. 6:203–208. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tas SW, Vervoordeldonk MJ and Tak PP: Gene
therapy targeting nuclear factor-kappaB: Towards clinical
application in inflammatory diseases and cancer. Curr Gene Ther.
9:160–170. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Medina M and Castro A: Glycogen synthase
kinase-3 (GSK-3) inhibitors reach the clinic. Curr Opin Drug Discov
Devel. 11:533–543. 2008.PubMed/NCBI
|
|
23
|
Walz A, Ugolkov A, Chandra S, Kozikowski
A, Carneiro BA, O'Halloran TV, Giles FJ, Billadeau DD and Mazar AP:
Molecular pathways: Revisiting glycogen synthase kinase-3β as a
target for the treatment of cancer. Clin Cancer Res. 23:1891–1897.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rizzieri DA, Cooley S, Odenike O, Moonan
L, Chow KH, Jackson K, Wang X, Brail L and Borthakur G: An
open-label phase 2 study of glycogen synthase kinase-3 inhibitor
LY2090314 in patients with acute leukemia. Leuk Lymphoma.
57:1800–1806. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dignam JD, Lebovitz RM and Roeder RG:
Accurate transcription initiation by RNA polymerase II in a soluble
extract from isolated mammalian nuclei. Nucleic Acids Res.
11:1475–1489. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ugolkov A, Gaisina I, Zhang JS, Billadeau
DD, White K, Kozikowski A, Jain S, Cristofanilli M, Giles F,
O'Halloran T, et al: GSK-3 inhibition overcomes chemoresistance in
human breast cancer. Cancer Lett. 380:384–392. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Quintayo MA, Munro AF, Thomas J, Kunkler
IH, Jack W, Kerr GR, Dixon JM, Chetty U and Bartlett JM: GSK3β and
cyclin D1 expression predicts outcome in early breast cancer
patients. Breast Cancer Res Treat. 136:161–168. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shin S, Wolgamott L, Tcherkezian J,
Vallabhapurapu S, Yu Y, Roux PP and Yoon SO: Glycogen synthase
kinase-3β positively regulates protein synthesis and cell
proliferation through the regulation of translation initiation
factor 4E-binding protein 1. Oncogene. 33:1690–1699. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Darrington RS, Campa VM, Walker MM,
Bengoa-Vergniory N, Gorrono-Etxebarria I, Uysal-Onganer P, Kawano
Y, Waxman J and Kypta RM: Distinct expression and activity of
GSK-3α and GSK-3β in prostate cancer. Int J Cancer. 131:E872–E883.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rask K, Nilsson A, Brännström M, Carlsson
P, Hellberg P, Janson PO, Hedin L and Sundfeldt K: Wnt-signalling
pathway in ovarian epithelial tumours: increased expression of
beta-catenin and GSK3beta. Br J Cancer. 89:1298–1304. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vincent EE, Elder DJ, O'Flaherty L, Pardo
OE, Dzien P, Phillips L, Morgan C, Pawade J, May MT, Sohail M, et
al: Glycogen synthase kinase 3 protein kinase activity is
frequently elevated in human non-small cell lung carcinoma and
supports tumour cell proliferation. PLoS One. 9:e1147252014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zeng J, Liu D, Qiu Z, Huang Y, Chen B,
Wang L, Xu H, Huang N, Liu L and Li W: GSK3β overexpression
indicates poor prognosis and its inhibition reduces cell
proliferation and survival of non-small cell lung cancer cells.
PLoS One. 9:e912312014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cho YJ, Yoon J, Ko YS, Kim SY, Cho SJ, Kim
WH, Park JW, Youn HD, Kim JH and Lee BL: Glycogen synthase
kinase-3β does not correlate with the expression and activity of
β-catenin in gastric cancer. APMIS. 118:782–790. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Salim T, Sjölander A and Sand-Dejmek J:
Nuclear expression of glycogen synthase kinase-3β and lack of
membranous β-catenin is correlated with poor survival in colon
cancer. Int J Cancer. 133:807–815. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pal K, Cao Y, Gaisina IN, Bhattacharya S,
Dutta SK, Wang E, Gunosewoyo H, Kozikowski AP, Billadeau DD and
Mukhopadhyay D: Inhibition of GSK-3 induces differentiation and
impaired glucose metabolism in renal cancer. Mol Cancer Ther.
13:285–296. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Carter YM, Kunnimalaiyaan S, Chen H,
Gamblin TC and Kunnimalaiyaan M: Specific glycogen synthase
kinase-3 inhibition reduces neuroendocrine markers and suppresses
neuroblastoma cell growth. Cancer Biol Ther. 15:510–515. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Duffy DJ, Krstic A, Schwarzl T, Higgins DG
and Kolch W: GSK3 inhibitors regulate MYCN mRNA levels and reduce
neuroblastoma cell viability through multiple mechanisms, including
p53 and Wnt signaling. Mol Cancer Ther. 13:454–467. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hilliard TS, Gaisina IN, Muehlbauer AG,
Gaisin AM, Gallier F and Burdette JE: Glycogen synthase kinase 3β
inhibitors induce apoptosis in ovarian cancer cells and inhibit
in-vivo tumor growth. Anticancer Drugs. 22:978–985. 2011.PubMed/NCBI
|
|
39
|
Kotliarova S, Pastorino S, Kovell LC,
Kotliarov Y, Song H, Zhang W, Bailey R, Maric D, Zenklusen JC, Lee
J and Fine HA: Glycogen synthase kinase-3 inhibition induces glioma
cell death through c-MYC, nuclear factor-kappaB, and glucose
regulation. Cancer Res. 68:6643–6651. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA
and Chen H: Inactivation of glycogen synthase kinase-3beta, a
downstream target of the raf-1 pathway, is associated with growth
suppression in medullary thyroid cancer cells. Mol Cancer Ther.
6:1151–1158. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhu Q, Yang J, Han S, Liu J, Holzbeierlein
J, Thrasher JB and Li B: Suppression of glycogen synthase kinase 3
activity reduces tumor growth of prostate cancer in vivo. Prostate.
71:835–845. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ugolkov A, Qiang W, Bondarenko G, Procissi
D, Gaisina I, James CD, Chandler J, Kozikowski A, Gunosewoyo H,
O'Halloran T, et al: Combination treatment with the GSK-3 inhibitor
9-ING-41 and CCNU cures orthotopic chemoresistant glioblastoma in
patient-derived xenograft models. Transl Oncol. 10:669–678. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ugolkov AV, Bondarenko GI, Dubrovskyi O,
Berbegall AP, Navarro S, Noguera R, O'Halloran TV, Hendrix MJ,
Giles FJ and Mazar AP: 9-ING-41, a small molecule glycogen
synthase-3 inhibitor, is active in neuroblastoma. Anticancer Drugs.
29:717–724. 2018.PubMed/NCBI
|
|
44
|
Kim SW, Roh J and Park CS:
Immunohistochemistry for pathologists: Protocols, pitfalls and
tips. J Pathol Transl Med. 50:411–418. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cheuk W and Chan JK: Subcellular
localization of immunohistochemical signals: Knowledge of the
ultrastructural or biologic features of the antigens helps predict
the signal localization and proper interpretation of immunostains.
Int J Surg Pathol. 12:185–206. 2004. View Article : Google Scholar : PubMed/NCBI
|
